|
|
|
Volumn 2, Issue 3, 2002, Pages 245-246
|
|
Cell Genesys reports long-term survival data in Phase II trial of GVAX.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER VACCINE;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
ARTICLE;
DOSE RESPONSE;
HUMAN;
IMMUNOLOGY;
MALE;
MORTALITY;
PHASE 2 CLINICAL TRIAL;
PROSTATE TUMOR;
SURVIVAL RATE;
SURVIVOR;
CANCER VACCINES;
CLINICAL TRIALS, PHASE II;
DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC;
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR;
HUMANS;
MALE;
PROSTATIC NEOPLASMS;
SURVIVAL RATE;
SURVIVORS;
|
|
EID: 0036598006
PISSN: 14737140
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|